semaglutide weight loss clinic lancaster Program in Hi everyone! 👋 There's still

Month 210: FDA Review The FDA conducts parallel reviews across five teams: Medical Review: Efficacy, safety, and dose selection

62% (tirzepatide) vs 37% (semaglutide) achieved 10% or greater weight loss and 42% (tirzepatide) vs 18% (semaglutide) achieved 15% or greater weight loss within a year

Either way, you likely need to be on top of these symptoms

The decision typically comes down to your primary complaint

Tirzepatide (Mounjaro/Zepbound), Eli Lillys dual GLP-1 + GIP agonist, is already growing faster than semaglutide in the US

GLP-1, and hence also semaglutide, slows the rate at which food is digested in the stomach, and acts on the brain to reduce appetite